Hormonal
Short-term ADT (3-6 months) induces insulin resistance and hyperinsulinemia while maintaining normal fasting glucose levels, whereas long-term ADT (12+ months) leads to frank hyperglycemia and diabetes.
Monitor your blood sugar closely. In the first few months of treatment, your body may compensate for insulin resistance by producing more insulin, keeping blood sugar normal. However, after a year, this compensation often fails, leading to diabetes. Regular glucose tolerance tests are recommended for those on long-term therapy.
Short-term ADT (3– 6 months) leads to the development of insulin resistance without resulting in hyperglycemia. However, long-term ADT (12 months or longer) is associated with hyperglycemia and frank diabetes.
Why this rating
Supported by multiple prospective studies showing hyperinsulinemia at 3 months and hyperglycemia at 12+ months.
Source
Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
Sadeka Shahani et al. · The Journal of Clinical Endocrinology & Metabolism · 2008
DOI 10.1210/jc.2007-2595
More from this paper
- Androgen deprivation therapy (ADT) for prostate cancer causes significant metabolic complications, including insulin resistance, hyperglycemia, and metabolic syndrome, which accelerate cardiovascular mortality.Good
- ADT causes unfavorable body composition changes, specifically increasing fat mass (particularly visceral/subcutaneous) and decreasing lean body mass, which correlates with rising insulin levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →